Additionally, the 36-month beta value for TLSA is 0.63. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TLSA is 121.18M and currently, short sellers hold a 0.10% ratio of that float. The average trading volume of TLSA on September 25, 2024 was 261.40K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TLSA) stock’s latest price update
Tiziana Life Sciences Ltd (NASDAQ: TLSA)’s stock price has gone decline by -9.77 in comparison to its previous close of 1.02, however, the company has experienced a 8.77% increase in its stock price over the last five trading days. proactiveinvestors.com reported 2024-09-19 that Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured a $4 million grant from the National Institutes of Health (NIH) to advance research of nasal anti-CD3 as a treatment for Alzheimer’s disease. The company has been developing a fully human, anti-CD3 monoclonal antibody called intranasal foramulab, which has demonstrated a favorable safety profile and clinical response in studies to date.
TLSA’s Market Performance
Tiziana Life Sciences Ltd (TLSA) has experienced a 8.77% rise in stock performance for the past week, with a -24.57% drop in the past month, and a -5.12% drop in the past quarter. The volatility ratio for the week is 14.85%, and the volatility levels for the past 30 days are at 10.90% for TLSA. The simple moving average for the past 20 days is -6.43% for TLSA’s stock, with a 24.51% simple moving average for the past 200 days.
Analysts’ Opinion of TLSA
Many brokerage firms have already submitted their reports for TLSA stocks, with B. Riley Securities repeating the rating for TLSA by listing it as a “Buy.” The predicted price for TLSA in the upcoming period, according to B. Riley Securities is $8 based on the research report published on December 22, 2020 of the previous year 2020.
TLSA Trading at -11.95% from the 50-Day Moving Average
After a stumble in the market that brought TLSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.11% of loss for the given period.
Volatility was left at 10.90%, however, over the last 30 days, the volatility rate increased by 14.85%, as shares sank -25.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.29% upper at present.
During the last 5 trading sessions, TLSA rose by +8.77%, which changed the moving average for the period of 200-days by +46.08% in comparison to the 20-day moving average, which settled at $0.9681. In addition, Tiziana Life Sciences Ltd saw 64.34% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for TLSA
The total capital return value is set at -2.58.
Based on Tiziana Life Sciences Ltd (TLSA), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -63.55. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -2083.71.
Currently, EBITDA for the company is -15.34 million with net debt to EBITDA at 0.06.
Conclusion
In conclusion, Tiziana Life Sciences Ltd (TLSA) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
